Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Washington Roundup, October 2012

Executive Summary

The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we cover FDA’s enforcement action against CardioMEMS for alleged clinical trial violations, medical device user fee agreement implementation, and AdvaMed’s priority list for the fiscal-cliff bill.

You may also be interested in...

User Fee Limbo: FDA Will Not Have Access To Extra Industry Funds At FY 2013 Start

The new fiscal year starts Oct. 1, but FDA will not be able to spend the full amount of fiscal year 2013 industry user fees as a result of an emergency spending bill, and Congress is not expected to fix the issue until after the election in November at the earliest.

Industry Praises PMA-Acceptance Draft Guidance, But Offers A Few Suggestions

Companies are generally happy with FDA’s July 31 draft guidance describing a 15-day "acceptance review" that FDA staff will perform to quickly check that a PMA submission meets minimum requirements.

FDA Aims To Reduce 510(k) Review Times With New Submission Acceptance Process

Draft guidance outlines criteria that 510(k) submissions must meet before the agency begins its substantive review.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts